Cochrane Abstracts
Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Certolizumab Pegol for Maintenance of Medically Induced Remission in Crohn’s disease." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/435915/all/Certolizumab_pegol_for_maintenance_of_medically_induced_remission_in_Crohn_s disease.
Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/435915/all/Certolizumab_pegol_for_maintenance_of_medically_induced_remission_in_Crohn_s disease. Accessed January 24, 2025.
Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/435915/all/Certolizumab_pegol_for_maintenance_of_medically_induced_remission_in_Crohn_s disease
Certolizumab Pegol for Maintenance of Medically Induced Remission in Crohn’s disease [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 January 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/435915/all/Certolizumab_pegol_for_maintenance_of_medically_induced_remission_in_Crohn_s disease.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease
ID - 435915
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/435915/all/Certolizumab_pegol_for_maintenance_of_medically_induced_remission_in_Crohn_s disease
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
